Quick Answer
RetinalGenix Technologies Inc. reported Stockholders Equity of -$1.46 million for the year ending 2024.
- RetinalGenix Technologies Inc. showed a decrease of -4.1% in Stockholders Equity from 2023 to 2024.
- This data is from RetinalGenix Technologies Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2019 to 2024 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$10.6 thousand | Q2 2020: -$128.8 thousand | Q3 2020: $134.0 thousand | Q1 2021: -$254.5 thousand | Q2 2021: -$35.7 thousand | Q3 2021: -$412.7 thousand | Q1 2022: -$724.3 thousand | Q2 2022: -$675.2 thousand | Q3 2022: -$1.06 million | Q1 2023: -$1.50 million | Q2 2023: -$1.77 million | Q3 2023: -$1.08 million | Q4 2023: -$1.41 million | Q1 2024: -$1.52 million | Q2 2024: -$1.81 million | Q3 2024: -$1.85 million | Q4 2024: -$1.46 million | Q1 2025: -$1.67 million | Q2 2025: -$1.98 million | Q3 2025: -$2.17 million.
- Over the full 6 years of available data (2019 to 2024), RetinalGenix Technologies Inc.'s Stockholders Equity has declined by 6,152.8%.
- Historical annual values: Fiscal year 2024: -$1.46 million | Fiscal year 2023: -$1.41 million | Fiscal year 2022: -$1.07 million | Fiscal year 2021: -$464.7 thousand | Fiscal year 2020: -$80.4 thousand | Fiscal year 2019: $24.2 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: